Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Donohue, J. M. Articles by Frank, R. G. Search for Related Content PubMed Citation Articles by Donohue, J. M. Articles by Frank, R. G. Social Security, Other Entitlements Atypical Neuroleptics Antidepressants Anxiolytics Related Article

Estimating Medicare Part D's Impact on Medication Access Among Dually Eligible Beneficiaries With Mental Disorders

OBJECTIVE: Medicare drug benefit (Part D) plans may restrict psychotropic medications more than state Medicaid programs do. This may have important implications for patients dually eligible for Medicare and Medicaid whose medications previously were covered under Medicaid. The objective of this study was to estimate rates of medication switching among dually eligible beneficiaries using antidepressants, antipsychotics, and mood stabilizers attributable to their enrollment in Medicare drug plans. METHODS: Baseline data on medication usage patterns among 467 dually eligible beneficiaries with mental disorders from the Medicare Current Beneficiary Survey, formulary data from a sample of Medicare drug plans, and estimates of the utilization response to pharmacy management tools from the Medicaid literature were used to estimate the likelihood of switching medications conditional on use of drugs and assignment to particular Medicare drug plans. RESULTS: Restrictions on psychotropic medications were common among the drug plans studied. Estimated rates of medication switching attributable to Medicare Part D were 6%–10% among dually eligible beneficiaries using antipsychotics, 5%–7% among those using antidepressants, and 2%–4% among those using mood stabilizers. Switching rates varied substantially across plans. CONCLUSIONS: On average, relatively few dually eligible beneficiaries with mental disorders are likely to experience treatment disruptions because of formulary restrictions and utilization controls used by Medicare drug plans. However, beneficiaries in some plans will experience significant barriers to medication access. Given the substantial variation among Medicare drug plans' management of psychotropic medication use, clinicians and social service agencies should counsel their beneficiaries with mental disorders in navigating the complex Medicare drug plan market.

Related Article:

October 2007: This Month's Highlights
Psychiatr Serv 2007 58: 1257. [Full Text] [PDF]

This article has been cited by other articles:

				J. M. Donohue, H. A. Huskamp, and S. H. Zuvekas Dual Eligibles With Mental Disorders And Medicare Part D: How Are They Faring? Health Aff., May 1, 2009; 28(3): 746 - 759. [Abstract] [Full Text] [PDF]

				A. S. Adams, F. Zhang, R. F. LeCates, A. J. Graves, D. Ross-Degnan, D. Gilden, T. J. McLaughlin, C. Lu, C. M. Trinacty, and S. B. Soumerai Prior Authorization for Antidepressants in Medicaid: Effects Among Disabled Dual Enrollees Arch Intern Med, April 27, 2009; 169(8): 750 - 756. [Abstract] [Full Text] [PDF]

				K. Jones, C. Siegel, D. N. Bertollo, and J. Samuels Impact of the Medicare Modernization Act on Dually Eligible Persons With Psychiatric Diagnoses: A New York State Case Study Psychiatr Serv, April 1, 2009; 60(4): 512 - 519. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us